RESUMO
Alcohol is harmful to the body, causing hepatic steatosis, alcoholic hepatitis and cirrhosis. The effects of alcohol on the liver can be offset using natural antioxidants. This study aimed to evaluate the effects of the administration of oral ß-carotene on the morphoquantitative characteristics of mice livers exposed to ethanol consumption. Forty-eight male mice were used, divided into six groups: Control (C), Low-dose alcohol (LA), Moderate-dose alcohol (MA), ß-carotene (B), Low-dose alcohol+ß-carotene (LA+B) and Moderate-dose alcohol+ß-carotene (MA+B). On day 28 the animals were euthanized and the organs were harvested. The morphoquantitative analysis, evaluation of the collagen fiber content and transmission electron microscopy were performed. A one-way ANOVA was used for statistical analysis. There were no differences between NVhep, VVhep, SVhep, VVbin, TVhep and TMhep in groups C and the MA+B (P < 0.001). The analysis of type I collagen fibers revealed that the MA+B group presented differences with groups C (P < 0.001), LA (P = 0.046) and LA+B (P = 0.009). The ultrastructural analysis for NAm, NVm, NTm, VVm, Vm, SVm and TSm did not reflect any significant differences between the groups. Our results suggest that the degree of hepatic steatosis produced by different doses of alcohol can be prevented. However, the following factors should be considered: amount of alcohol consumed, exposure time, regulatory mechanisms of alcoholic liver disease and signaling pathways involved in the ingestion of both ethanol and antioxidants.
RESUMO
The objective of this study was to evaluate the association of vitamin D intake and serum levels with fracture risk in children under 6 years of age. A case-control study was conducted in Toronto, Ontario, Canada. Cases were recruited from the fracture clinic at the Hospital for Sick Children, and matched controls were obtained from the TARGet Kids! primary-care research network. Controls were matched to cases on age, sex, height, and season. Fracture risk was estimated from conditional logistic regression, with adjustment for skin type, fracture history, waist circumference, outdoor free play, neighborhood income, soda consumption, and child's birth weight. A total of 206 cases were recruited during May 2009-April 2013 and matched to 343 controls. Serum 25-hydroxyvitamin D concentration (per 10-nmol/L increment: adjusted odds ratio (aOR) = 0.95, 95% confidence interval (CI): 0.88, 1.03) and intake of cow's milk (<2 cups/day vs. 2 cups/day: aOR = 0.95 (95% CI: 0.60, 1.52); >2 cups/day vs. 2 cups/day: aOR = 1.39 (95% CI: 0.85, 2.23)) were not significantly associated with reduced odds of fracture. A statistically significant association was observed between child use of vitamin D supplements and decreased odds of fracture (yes vs. no: aOR = 0.42, 95% CI: 0.25, 0.69). Vitamin D supplementation, but not serum 25-hydroxyvitamin D level or milk intake, was associated with reduced fracture risk among these healthy young children.
Assuntos
Suplementos Nutricionais , Ingestão de Alimentos , Fraturas Ósseas/etiologia , Leite , Vitamina D/análogos & derivados , Animais , Estudos de Casos e Controles , Pré-Escolar , Feminino , Fraturas Ósseas/epidemiologia , Humanos , Lactente , Modelos Logísticos , Masculino , Razão de Chances , Ontário/epidemiologia , Fatores de Risco , Vitamina D/administração & dosagem , Vitamina D/sangue , Vitaminas/administração & dosagemRESUMO
Non-alcoholic steatohepatitis (NASH), is the form of non-alcoholic fatty liver disease posing risk to progress into serious long term complications. Human and pre-clinical models implicate cellular cholesterol dysregulation playing important role in its development. Mouse model studies suggest synergism between dietary cholesterol and fat in contributing to NASH but the mechanisms remain poorly understood. Our laboratory previously reported the primary importance of hepatic endoplasmic reticulum cholesterol (ER-Chol) in regulating hepatic ER stress by comparing the responses of wild type, Ldlr-/-xLcat+/+ and Ldlr-/-xLcat-/- mice, to a 2% high cholesterol diet (HCD). Here we further investigated the roles of ER-Chol and ER stress in HFHS diet-induced NASH using the same strains. With HFHS diet feeding, both WT and Ldlr-/-xLcat+/+ accumulate ER-Chol in association with ER stress and inflammasome activation but the Ldlr-/-xLcat-/- mice are protected. By contrast, all three strains accumulate cholesterol crystal, in correlation with ER-Chol, albeit less so in Ldlr-/-xLcat-/- mice. By comparison, HCD feeding per se (i) is sufficient to promote steatosis and activate inflammasomes, and (ii) results in dramatic accumulation of cholesterol crystal which is linked to inflammasome activation in Ldlr-/-xLcat-/- mice, independent of ER-Chol. Our data suggest that both dietary fat and cholesterol each independently promote steatosis, cholesterol crystal accumulation and inflammasome activation through distinct but complementary pathways. In vitro studies using palmitate-induced hepatic steatosis in HepG2 cells confirm the key roles by cellular cholesterol in the induction of steatosis and inflammasome activations. These novel findings provide opportunities for exploring a cellular cholesterol-focused strategy for treatment of NASH.
Assuntos
Colesterol na Dieta/metabolismo , Estresse do Retículo Endoplasmático/efeitos dos fármacos , Fígado/metabolismo , Hepatopatia Gordurosa não Alcoólica/genética , Fosfatidilcolina-Esterol O-Aciltransferase/genética , Receptores de LDL/genética , Animais , Colesterol na Dieta/efeitos adversos , Dieta Hiperlipídica/efeitos adversos , Modelos Animais de Doenças , Estresse do Retículo Endoplasmático/genética , Feminino , Regulação da Expressão Gênica , Células Hep G2 , Humanos , Inflamassomos/efeitos dos fármacos , Inflamassomos/metabolismo , Deficiência da Lecitina Colesterol Aciltransferase/genética , Deficiência da Lecitina Colesterol Aciltransferase/metabolismo , Metabolismo dos Lipídeos/genética , Fígado/patologia , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Hepatopatia Gordurosa não Alcoólica/etiologia , Hepatopatia Gordurosa não Alcoólica/metabolismo , Hepatopatia Gordurosa não Alcoólica/fisiopatologia , Oxirredução , Ácido Palmítico/farmacologia , Fosfatidilcolina-Esterol O-Aciltransferase/metabolismo , Receptores de LDL/deficiência , Transdução de SinaisRESUMO
BACKGROUND: Poor vitamin D status (i.e. low serum 25-hydroxyvitamin D (25(OH)D)) has been associated with adverse clinical outcomes during pregnancy and childhood. However, the interpretation of serum 25(OH)D levels may be complicated by the presence of the C3-epimer of 25(OH)D. We aimed to quantify C3-epi-25(OH)D3 in pregnant women and fetuses, to explore the relationship of the C3-epimer between maternal and cord samples, and to establish whether infant C3-epimer abundance is explained by prenatal formation. METHODS: In a sub-study of a randomized trial of prenatal vitamin D3, 25(OH)D3 and C3-epi-25(OH)D3 were quantified by LC-MS/MS in 71 sets of mother-fetus-infant serum samples, including maternal delivery specimens, cord blood, and infant specimens acquired at 3-28 weeks of age. RESULTS: Without supplementation, median concentrations of C3-epi-25(OH)D3 were higher in infants (6.80 nmol/L) than mothers (0.45 nmol/L) and cord blood (0 nmol/L). However, there was substantial variation such that C3-epi-25(OH)D3 accounted for up to 11% (maternal), 14% (cord), and 25% (infant) of the total 25(OH)D3. Supplemental vitamin D3 significantly increased maternal-fetal C3-epi-25(OH)D3, and was a preferential source of C3-epi-25(OH)D3 compared to basal vitamin D, possibly due to C3-epi-cholecalciferol in the supplement. Multivariate regression did not suggest transplacental transfer of C3-epi-25(OH)D3, but rather indicated its generation within the fetal-placental unit from maternally-derived 25(OH)D3. Neither maternal nor fetal C3-epi-25(OH)D3 is accounted for the relatively high concentrations of infant C3-epi-25(OH)D3, suggesting rapid postnatal generation. CONCLUSIONS: C3-epi-25(OH)D3 is present in some pregnant women and fetuses, but does not appear to be efficiently transferred transplacentally. High C3-epimer concentrations in infancy are probably due to postnatal formation rather than fetal stores.
Assuntos
Colecalciferol/administração & dosagem , Complicações na Gravidez/sangue , Deficiência de Vitamina D/sangue , Vitamina D/análogos & derivados , Vitaminas/administração & dosagem , Adulto , Colecalciferol/farmacocinética , Método Duplo-Cego , Feminino , Sangue Fetal/metabolismo , Humanos , Lactente , Recém-Nascido , Troca Materno-Fetal , Gravidez , Complicações na Gravidez/tratamento farmacológico , Ensaios Clínicos Controlados Aleatórios como Assunto , Espectrometria de Massas em Tandem , Vitamina D/sangue , Deficiência de Vitamina D/tratamento farmacológico , Vitaminas/farmacocinéticaRESUMO
The glucagon-like peptides (GLP-1 and GLP-2) are processed from the proglucagon polypeptide and secreted in equimolar amounts but have opposite effects on chylomicron (CM) production, with GLP-1 significantly reducing and GLP-2 increasing postprandial chylomicronemia. In the current study, we evaluated the apparent paradoxical roles of GLP-1 and GLP-2 under physiological conditions in the Syrian golden hamster, a model with close similarity to humans in terms of lipoprotein metabolism. A short (30-min) intravenous infusion of GLP-2 resulted in a marked increase in postprandial apolipoprotein B48 (apoB48) and triglyceride (TG) levels in the TG-rich lipoprotein (TRL) fraction, whereas GLP-1 infusion decreased lipid absorption and levels of TRL-TG and apoB48. GLP-1 and GLP-2 coinfusion resulted in net increased lipid absorption and an increase in TRL-TG and apoB48. However, prolonged (120-min) coinfusion of GLP-1 and GLP-2 decreased postprandial lipemia. Blocking dipeptidyl peptidase-4 activity resulted in decreased postprandial lipemia. Interestingly, fructose-fed, insulin-resistant hamsters showed a more pronounced response, including possible hypersensitivity to GLP-2 or reduced sensitivity to GLP-1. In conclusion, under normal physiological conditions, the actions of GLP-2 predominate; however, when GLP-1 activity is sustained, the hypolipidemic action of GLP-1 predominates. Pharmacological inhibition of GLP-1 degradation tips the balance toward an inhibitory effect on intestinal production of atherogenic CM particles.
Assuntos
Peptídeo 1 Semelhante ao Glucagon/administração & dosagem , Peptídeo 2 Semelhante ao Glucagon/administração & dosagem , Hiperlipidemias/metabolismo , Resistência à Insulina/fisiologia , Intestinos/efeitos dos fármacos , Lipoproteínas/biossíntese , Período Pós-Prandial/efeitos dos fármacos , Animais , Apolipoproteína B-48/biossíntese , Quilomícrons/biossíntese , Quilomícrons/efeitos dos fármacos , Cricetinae , Inibidores da Dipeptidil Peptidase IV/farmacologia , Frutose/administração & dosagem , Hiperlipidemias/sangue , Absorção Intestinal/efeitos dos fármacos , Metabolismo dos Lipídeos/efeitos dos fármacos , Masculino , Mesocricetus , Triglicerídeos/sangue , Triglicerídeos/metabolismoRESUMO
With an ever-increasing clinical interest in vitamin D insufficiency, numerous automated immunoassays, protein binding assays, and in-house LC-MS/MS methods are being developed for the quantification of 25-hydroxyvitamin D(3) (25(OH)D(3)). Recently, LC-MS/MS methods have identified an epimeric form of 25(OH)D(3) that has been shown to contribute significantly to 25(OH)D(3) concentration, particularly in infant populations. This review describes the metabolic pathway and physiological functions of 3-epi-vitamin D, compares the capability of various 25(OH)D(3) methods to detect the epimer, and highlights recent publications quantifying 3-epi-25(OH)D(3) in infant, pediatric, and adult populations. In total, this review summarizes the information necessary for clinicians and laboratorians to decide whether or not to report/consider the C3-epimer in the analysis and clinical assessment of vitamin D status.
Assuntos
Calcifediol/análogos & derivados , Calcifediol/análise , Suplementos Nutricionais/análise , Fatores Etários , Calcifediol/metabolismo , Calcitriol/análise , Calcitriol/metabolismo , Cálcio/metabolismo , Cromatografia Líquida/métodos , Testes de Química Clínica/métodos , Humanos , Limite de Detecção , Espectrometria de Massas/métodos , Reprodutibilidade dos Testes , Esteroide Hidroxilases/metabolismo , Deficiência de Vitamina D/diagnóstico , Vitamina D3 24-HidroxilaseRESUMO
ETC-1002 (8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid) is a novel investigational drug being developed for the treatment of dyslipidemia and other cardio-metabolic risk factors. The hypolipidemic, anti-atherosclerotic, anti-obesity, and glucose-lowering properties of ETC-1002, characterized in preclinical disease models, are believed to be due to dual inhibition of sterol and fatty acid synthesis and enhanced mitochondrial long-chain fatty acid ß-oxidation. However, the molecular mechanism(s) mediating these activities remained undefined. Studies described here show that ETC-1002 free acid activates AMP-activated protein kinase in a Ca(2+)/calmodulin-dependent kinase ß-independent and liver kinase ß 1-dependent manner, without detectable changes in adenylate energy charge. Furthermore, ETC-1002 is shown to rapidly form a CoA thioester in liver, which directly inhibits ATP-citrate lyase. These distinct molecular mechanisms are complementary in their beneficial effects on lipid and carbohydrate metabolism in vitro and in vivo. Consistent with these mechanisms, ETC-1002 treatment reduced circulating proatherogenic lipoproteins, hepatic lipids, and body weight in a hamster model of hyperlipidemia, and it reduced body weight and improved glycemic control in a mouse model of diet-induced obesity. ETC-1002 offers promise as a novel therapeutic approach to improve multiple risk factors associated with metabolic syndrome and benefit patients with cardiovascular disease.
Assuntos
Proteínas Quinases Ativadas por AMP/metabolismo , ATP Citrato (pro-S)-Liase/metabolismo , Metabolismo dos Carboidratos/efeitos dos fármacos , Ácidos Dicarboxílicos/farmacologia , Inibidores Enzimáticos/farmacologia , Ácidos Graxos/farmacologia , Metabolismo dos Lipídeos/efeitos dos fármacos , Terapia de Alvo Molecular/métodos , Quinases Proteína-Quinases Ativadas por AMP , ATP Citrato (pro-S)-Liase/antagonistas & inibidores , Animais , Biomarcadores/sangue , Biomarcadores/metabolismo , Cálcio/metabolismo , Cricetinae , Ácidos Dicarboxílicos/química , Ácidos Dicarboxílicos/uso terapêutico , Dieta/efeitos adversos , Dislipidemias/sangue , Dislipidemias/tratamento farmacológico , Dislipidemias/metabolismo , Metabolismo Energético/efeitos dos fármacos , Ativação Enzimática/efeitos dos fármacos , Inibidores Enzimáticos/química , Inibidores Enzimáticos/uso terapêutico , Ácidos Graxos/biossíntese , Ácidos Graxos/química , Ácidos Graxos/uso terapêutico , Feminino , Glucagon/metabolismo , Glucose/biossíntese , Células Hep G2 , Humanos , Fígado/citologia , Fígado/efeitos dos fármacos , Fígado/enzimologia , Fígado/metabolismo , Masculino , Camundongos , Obesidade/sangue , Obesidade/tratamento farmacológico , Obesidade/etiologia , Obesidade/metabolismo , Proteínas Serina-Treonina Quinases/metabolismo , Ratos , Transdução de Sinais/efeitos dos fármacos , Esteróis/biossínteseRESUMO
OBJECTIVES: To develop a simple and sensitive LC-MS/MS procedure for quantification of serum 25-OH-vitamin D3 (25-OH-D3), 25-OH-vitamin D2 (25-OH-D2), and their C3-epimers. METHODS: Serum 25-OH-vitamin D metabolites were extracted with MTBE and quantified by LC-MS/MS. Commercially available calibrators and QC materials were employed. The ion-transition 401.2â365.2 was monitored for 25-OH-D3 and C3-epi-25-OH-D3, 407.2â371.3 for d6-25-OH-D3, 413.2â331.2 for 25-OH-D2 and C3-epi-25-OH-D2 and 419.2â337.1 for, d6-25-OH-D2. As a proof-of-principle, 25-OH-D3 and C3-epi-25-OH-D3 were quantified in 200 pediatric subjects (0-20 years of age). Cholecalciferol supplements were examined as a potential source of C3-epimer. RESULTS: The assay provided an LLOQ of ≤2.8 nmol/L for all 25-OH-D metabolites, with a linear response up to 400 nmol/L. The CV was <10% for 25-OH-D2/3 and <15% for C3-epi-25-OH-D3. C3-epi-25-OH-D3 was quantified in all subjects, with higher concentrations observed in infants ≤1 year of age (11.44 nmol/L vs. 4.4 nmol/L; p<0.001). Within the first year of life, 25-OH-D3 concentrations increased linearly, while C3-epi-25-OH-D3 concentrations remained constant. At 12 months of age, C3-epi-25-OH-D3 concentration dropped by almost 50% (11.4 nmol/L in infants ≤1year of age vs. 5.4 nmol/L in infants 1-2years of age; p<0.001). Liquid vitamin D3 supplements did not contain appreciable amounts of C3-epi-D3. CONCLUSIONS: The proposed LC-MS/MS procedure is suitable for quantifying 25-OH-D3 metabolites. Although the C3-epimer is present in all pediatric subjects, it is significantly elevated in individuals ≤1 year of age and drops at 12 months of age. Oral vitamin D supplements are unlikely to be a significant source of C3-vitamin D epimer.
Assuntos
Colecalciferol/sangue , Ergocalciferóis/sangue , Vitamina D/sangue , Adolescente , Adulto , Criança , Pré-Escolar , Colecalciferol/química , Colecalciferol/metabolismo , Cromatografia Líquida , Ergocalciferóis/química , Ergocalciferóis/metabolismo , Feminino , Humanos , Lactente , Recém-Nascido , Masculino , Espectrometria de Massas em Tandem , Vitamina D/química , Vitamina D/metabolismoRESUMO
RATIONALE: Dysregulation of hepatic triglyceride (TG)-rich very low-density lipoproteins (VLDL-TG) in obesity and type 2 diabetes contributes to the dyslipidemia that leads to cardiovascular morbidity. The central nervous system (CNS), particularly the hypothalamus, regulates hepatic lipid metabolism. Although the underlying neurocircuitry remains elusive, glycine has been documented to enhance CNS N-methyl-d-aspartate (NMDA) receptor-mediated transmission. OBJECTIVE: We tested the hypothesis that glycine regulates hepatic VLDL-TG secretion by potentiating NMDA receptor-mediated transmission in the CNS. METHODS AND RESULTS: Using 10-hour fasted male Sprague-Dawley rats implanted with stereotaxic cannulae into an extrahypothalamic region termed the dorsal vagal complex (DVC) and vascular catheters to enable direct DVC infusion and blood sampling, respectively, the rate of hepatic VLDL-TG secretion was measured following tyloxapol (an inhibitor of lipoprotein lipase) injection. Direct DVC infusion of glycine lowered VLDL-TG secretion, whereas NMDA receptor blocker MK-801 fully negated glycine's effect. NR1 subunit of NMDA receptor antagonist 7-chlorokynurenic acid, adenoviral injection of NR1 short hairpin RNA (shRNA), and hepatic vagotomy also nullified glycine's effect. Finally, DVC glycine normalized the hypersecretion of VLDL-TG induced by high-fat feeding. CONCLUSIONS: Molecular and pharmacological inhibition of the NR1-containing NMDA receptors in the DVC negated the ability of glycine to inhibit hepatic secretion of VLDL-TG in vivo. Importantly, the hypersecretion of VLDL-TG from the liver induced by a model of high-fat feeding was restored by the hepatic lipid control of CNS glycine sensing. These findings collectively suggest that glycine or glycine analogues may have therapeutic benefits in lowering plasma lipid levels in diabetes and obesity by triggering the CNS.
Assuntos
VLDL-Colesterol/metabolismo , Glicina/metabolismo , Hipotálamo/metabolismo , Fígado/metabolismo , Triglicerídeos/metabolismo , Adiponectina/sangue , Animais , Diabetes Mellitus Tipo 2/tratamento farmacológico , Diabetes Mellitus Tipo 2/metabolismo , Gorduras na Dieta/farmacologia , Dislipidemias/tratamento farmacológico , Dislipidemias/metabolismo , Ácidos Graxos não Esterificados/sangue , Glicina/farmacologia , Insulina/sangue , Leptina/sangue , Metabolismo dos Lipídeos/efeitos dos fármacos , Metabolismo dos Lipídeos/fisiologia , Fígado/efeitos dos fármacos , Masculino , Obesidade/tratamento farmacológico , Obesidade/metabolismo , Ratos , Ratos Sprague-Dawley , Receptores de N-Metil-D-Aspartato/metabolismo , Estearoil-CoA Dessaturase/antagonistas & inibidores , Estearoil-CoA Dessaturase/metabolismo , VagotomiaRESUMO
Ghrelin, released from the stomach, acts at the hypothalamus and is associated with initiation of food intake. We hypothesised that patients with craniopharyngioma and hypothalamic obesity (CRHO) would have ghrelin abnormalities. Fifteen CRHO patients and 15 BMI-matched controls underwent oral glucose tolerance test with dynamic ghrelin measurement. From 0-30 minutes, ghrelin (pg/ml) decreased less (43.4 ? 38.8 vs. 70.8 ? 35.8, p < 0.05) and insulin (pmol/l) increased more (1 669.2 ? 861.7 vs. 1 049.1 ? 560.4, p = 0.04) in CRHO compared with controls, respectively. Insulin area-under-the-curve was a weak negative predictor of the 0?30 minutes ghrelin decrease (r(2) = 0.29, p = 0.02). Delayed ghrelin suppression may contribute to obesity in CRHO.
Assuntos
Craniofaringioma/complicações , Grelina/sangue , Teste de Tolerância a Glucose , Hipotálamo/metabolismo , Obesidade/etiologia , Neoplasias Hipofisárias/complicações , Adolescente , Fatores Etários , Biomarcadores/sangue , Glicemia/metabolismo , Índice de Massa Corporal , Estudos de Casos e Controles , Criança , Craniofaringioma/sangue , Craniofaringioma/fisiopatologia , Feminino , Humanos , Hipotálamo/fisiopatologia , Insulina/sangue , Modelos Lineares , Masculino , Obesidade/sangue , Obesidade/fisiopatologia , Neoplasias Hipofisárias/sangue , Neoplasias Hipofisárias/fisiopatologia , Medição de Risco , Fatores de Risco , Fatores de TempoRESUMO
OBJECTIVE: This trial aimed to evaluate the effects of zinc sulfate in comparison with placebo on markers of insulin resistance, oxidative stress, and inflammation in a sample of obese prepubescent children. METHODS: This triple-masked, randomized, placebo-controlled, crossover trial was conducted among 60 obese Iranian children in 2008. Participants were randomly assigned to two groups of equal number; one group received 20 mg of elemental zinc and the other group received placebo on a regular daily basis for 8 weeks. After a 4-week washout period, the groups were crossed over. In addition to anthropometric measures and blood pressure, fasting plasma glucose, lipid profile, insulin, apolipoproteins A-1 (ApoA-I) and B, high-sensitivity C-reactive protein (hs-CRP), leptin, oxidized low-density lipoprotein (ox-LDL), and malondialdehyde were determined at all four stages of the study. RESULTS: Irrespective of the order of receiving zinc and placebo, in both groups, significant decrease was documented for Apo B/ApoA-I ratio, ox-LDL, leptin and malondialdehyde, total and LDL-cholesterol after receiving zinc without significant change after receiving placebo. In groups, hs-CRP and markers of insulin resistance decreased significantly after receiving zinc, but increased after receiving placebo. In both groups, the mean body mass index (BMI) Z-score remained high, after receiving zinc, the mean weight, BMI, BMI Z-score decreased significantly, whereas these values increased after receiving placebo. CONCLUSION: These results are particularly important in light of the deleterious consequences of childhood obesity and early changes in markers of inflammatory and oxidative stress. We suggest exploring the direct clinical application of zinc supplementation in childhood obesity in future studies.
Assuntos
Biomarcadores/metabolismo , Suplementos Nutricionais , Inflamação/metabolismo , Resistência à Insulina , Síndrome Metabólica/metabolismo , Estresse Oxidativo/efeitos dos fármacos , Zinco/farmacologia , Biomarcadores/análise , Criança , Estudos Cross-Over , Método Duplo-Cego , Feminino , Humanos , Inflamação/complicações , Resistência à Insulina/fisiologia , Masculino , Síndrome Metabólica/complicações , Síndrome Metabólica/dietoterapia , Síndrome Metabólica/imunologia , Placebos , Puberdade/metabolismo , Puberdade/fisiologia , Zinco/administração & dosagem , Zinco/uso terapêuticoRESUMO
BACKGROUND: Craniopharyngioma (CP), a tumour occurring in the hypothalamic-pituitary area, results in morbid obesity in 25-60% of affected children. It has been suggested that abnormalities of insulin secretion and/or insulin action due to hypothalamic injury may be associated with weight gain and the metabolic syndrome in this population. AIM: To evaluate: (i) insulin secretion (IS) and insulin sensitivity (Si); (ii) features of the metabolic syndrome (MS) and (iii) factors involved in risk for diabetes and heart disease in obese youth treated for CP. METHODS: Obese subjects treated for CP were compared to BMI-matched control subjects. All subjects underwent anthropometric, blood pressure, resting energy expenditure and body fat assessment. Cholesterol and inflammatory markers, oral glucose tolerance test (OGTT) and frequent sampling intravenous glucose tolerance test (FSIGT), with calculation of IS and Si, were performed. RESULTS: Fifteen CP subjects and 15 controls (C) were studied. There were no differences between CP and C for age, gender, BMI or pubertal status. MS was present in 10/15 CP and 3/15 C (P = 0.03), including impaired glucose tolerance (IGT) in 6/15 CP and 0/15 C (P = 0.02). Measures of IS, including first and second phase IS, and insulin area-under-the-curve (AUC(ins)) during OGTT, were significantly higher in CP. Si, measured by frequent sampled intravenous glucose tolerance test (Si-FSIGT), was significantly lower in CP subjects (0.96 +/- 0.34 vs. 1.67 +/- 0.7; P = 0.01). AUC(ins) was negatively correlated with Si-FSIGT (r = -0.62; P = 0.003). CONCLUSION: Children with CP and hypothalamic obesity have more features of MS, increased IS and IGT prevalence and lower Si compared with BMI-matched controls.
Assuntos
Craniofaringioma/cirurgia , Resistência à Insulina , Obesidade/fisiopatologia , Neoplasias Hipofisárias/cirurgia , Complicações Pós-Operatórias/fisiopatologia , Adolescente , Estudos de Casos e Controles , Criança , Dislipidemias/complicações , Feminino , Teste de Tolerância a Glucose , Humanos , Hipertensão/complicações , Hipotálamo/lesões , Insulina/metabolismo , Secreção de Insulina , Masculino , Obesidade/complicações , Obesidade/metabolismo , Complicações Pós-Operatórias/etiologia , Complicações Pós-Operatórias/metabolismo , Adulto JovemRESUMO
We have reported previously that a cinnamon extract (CE), high in type A polyphenols, prevents fructose feeding-induced decreases in insulin sensitivity and suggested that improvements of insulin sensitivity by CE were attributable, in part, to enhanced insulin signaling. In this study, we examined the effects of CE on postprandial apolipoprotein (apo) B-48 increase in fructose-fed rats, and the secretion of apoB48 in freshly isolated intestinal enterocytes of fructose-fed hamsters. In an olive oil loading study, a water-soluble CE (Cinnulin PF, 50 mg/kg body weight, orally) decreased serum triglyceride (TG) levels and the over production of total- and TG-rich lipoprotein-apoB48. In ex vivo (35)S labeling study, significant decreases were also observed in apoB48 secretion into the media in enterocytes isolated from fructose-fed hamsters. We also investigated the molecular mechanisms of the effects of CE on the expression of genes of the insulin signaling pathway [insulin receptor (IR), IR substrate (IRS)1, IRS2 and Akt1], and lipoprotein metabolism [microsomal TG transfer protein (MTP), sterol regulatory element-binding protein (SREBP1c) in isolated primary enterocytes of fructose-fed hamsters, using quantitative real-time polymerase chain reaction. The CE reversed the expression of the impaired IR, IRS1, IRS2 and Akt1 mRNA levels and inhibited the overexpression of MTP and SREBP1c mRNA levels of enterocytes. Taken together, our data suggest that the postprandial hypertriglycerides and the overproduction of apoB48 can be acutely inhibited by a CE by a mechanism involving improvements of insulin sensitivity of intestinal enterocytes and regulation of MTP and SREBP1c levels. We present both in vivo and ex vivo evidence that a CE improves the postprandial overproduction of intestinal apoB48-containing lipoproteins by ameliorating intestinal insulin resistance and may be beneficial in the control of lipid metabolism.
Assuntos
Apolipoproteína B-48/biossíntese , Cinnamomum zeylanicum/química , Carboidratos da Dieta/farmacologia , Frutose/farmacologia , Extratos Vegetais/farmacologia , Período Pós-Prandial/fisiologia , Ração Animal , Animais , Proteínas de Transporte/biossíntese , Colesterol/sangue , Cricetinae , Enterócitos/efeitos dos fármacos , Enterócitos/metabolismo , Proteínas Substratos do Receptor de Insulina/biossíntese , Resistência à Insulina/fisiologia , Masculino , Mesocricetus , Período Pós-Prandial/efeitos dos fármacos , Proteínas Proto-Oncogênicas c-akt/biossíntese , RNA Mensageiro/metabolismo , Ratos , Ratos Wistar , Proteína de Ligação a Elemento Regulador de Esterol 1/biossíntese , Triglicerídeos/sangueRESUMO
Aqueous extracts or juice from unripened fruit of Momordica charantia (bitter melon) has traditionally been used in the treatment of diabetes and its complications. Insulin resistance is characterized by significant down-regulation of hepatic insulin signalling as documented by attenuated phosphorylation of insulin receptor (IR), IR substrates 1 and 2, phosphoinositide-3 kinase, protein kinase B, and over-expression of phosphotyrosine phosphatase 1B. We recently demonstrated that bitter melon juice (BMJ) is a potent inhibitor of apoB secretion and TAG synthesis and secretion in human hepatoma cells, HepG2, that may be involved in plasma lipid- and VLDL-lowering effects observed in animal studies. The aim of this study was to evaluate the effects of BMJ on plasma apoB levels and hepatic insulin signalling cascade in mice fed high-fat diet (HFD). Female C57BL/6 mice (4-6 weeks old) were randomized into three groups receiving regular rodent chow, HFD and HFD+BMJ. The data indicate that BMJ not only improves glucose and insulin tolerance but also lowers plasma apoB-100 and apoB-48 in HFD-fed mice as well as modulates the phosphorylation status of IR and its downstream signalling molecules. Investigating the biochemical and molecular mechanisms involved in amelioration of diabetic dyslipidaemia by BMJ may lead to identification of new molecular targets for dietary/alternative therapies.
Assuntos
Apolipoproteína B-100/sangue , Fígado/metabolismo , Momordica charantia , Fosfatidilinositol 3-Quinases/metabolismo , Extratos Vegetais/farmacologia , Receptor de Insulina/metabolismo , Animais , Apolipoproteína B-48/sangue , Gorduras na Dieta/administração & dosagem , Feminino , Resistência à Insulina , Camundongos , Camundongos Endogâmicos C57BL , Distribuição AleatóriaRESUMO
The present study evaluated the effect of green tea (Camellia sinensis L.) leaf extract on triglyceride and glucose homeostasis in a fructose-fed hypertriglyceridemic, insulin-resistant hamster model. There was a significant decrease in plasma triglyceride levels following supplementation of the green tea epigallocatechin gallate-enriched extract (42% at 150 mg/(kg day) to 62% at 300 mg/(kg day) for 4 weeks). Compared to baseline, the fructose control group at the end of the study showed elevated serum insulin and apolipoprotein B levels, and decreased serum adiponectin levels. The fructose/green tea extract group showed a reversal in all of these metabolic defects, including an improvement in glucose levels during a glucose tolerance test. Triglyceride content was also examined in various tissues and compared to the control fructose group; supplementation of the green tea extract (300 mg/kg) reduced triglyceride content in liver and heart tissues. There was molecular evidence of improved lipid and glucose homeostasis based on peroxisome proliferator-activated receptor (PPAR) protein expression. Compared to the control fructose group, supplementation of the green tea extract (300 mg/kg) significantly increased PPARalpha and PPARgamma protein expression. In summary, the data suggest that intake of the green tea extract ameliorated the fructose-induced hypertriglyceridemia and the insulin-resistant state in part through PPAR.
Assuntos
Glicemia/efeitos dos fármacos , Modelos Animais de Doenças , Frutose/administração & dosagem , Resistência à Insulina/fisiologia , Lipídeos/sangue , Chá , Animais , Glicemia/metabolismo , Cricetinae , Homeostase/efeitos dos fármacos , Homeostase/fisiologia , Masculino , Mesocricetus , Extratos Vegetais/isolamento & purificação , Extratos Vegetais/farmacologia , Folhas de PlantaRESUMO
Hepatic lipoprotein overproduction in a fructose-fed hamster model of insulin resistance was previously shown to be associated with a significant elevation of intracellular mass of microsomal triglyceride transfer protein (MTP) and elevated plasma levels of free fatty acids (FFA). Here, we further establish that fructose feeding and development of an insulin resistant state result in higher levels of MTP mRNA, protein mass, and lipid transfer activity. MTP protein mass was increased in fructose-fed hamster hepatocytes to 161 +/- 35.8% of control (p < 0.05), while MTP mRNA levels and MTP lipid transfer activity were increased to 147.5 +/- 30.8% (p < 0.05) and 177.5 +/- 14.5% (p < 0.05) of control levels, respectively. To identify underlying mechanisms, we also investigated the potential link between enhanced FFA flux and hepatic MTP gene expression. Direct modulation of MTP gene transcription by fatty acids was investigated by transfecting HepG2 cells with a reporter (luciferase) construct containing various base pair regions of the human MTP promoter including pMTP124 (with the sterol response element (SRE)), pMTP116, pMTP109 and pMTP100 (no SRE), and pMTP124SREKO (SRE sequences mutated). Treatment of HepG2 cells with oleic acid (360 muM) significantly increased luciferase activities in cells transfected with pMTP124 (136.6 +/- 11.0%, p < 0.05) and pMTP124SREKO (153.9 +/- 11.1%, p < 0.01) compared with control. Luciferase activity was also increased in a time and dose-dependent manner in the presence of oleic acid when transfected with pMTP124SREKO but not pMTP109 and pMTP100. Furthermore, long-term oleic acid treatment of HepG2 cells (10 days) induced higher levels of MTP mRNA (p < 0.05) confirming transcriptional stimulation of the MTP gene by oleic acid. In contrast, palmitate, arachidonic acid or linoleic acid did not significantly stimulate pMTP124 or pMTP124SREKO luciferase activity (p > 0.05). These data demonstrate that (1) MTP gene transcription may be directly up-regulated by oleic acid; (2) up-regulation of MTP gene transcription by oleic acid is SRE sequence independent; and (3) the sequence -116 to -109 in the MTP promoter region is essential for oleic acid-mediated stimulation. Stimulation of MTP gene expression may be a novel mechanism by which certain FFAs can induce hepatic lipoprotein secretion in insulin resistant states.
Assuntos
Proteínas de Transporte/genética , Resistência à Insulina/genética , Microssomos Hepáticos/metabolismo , Ácido Oleico/farmacologia , Regiões Promotoras Genéticas/genética , Animais , Sequência de Bases , Linhagem Celular Tumoral , Cricetinae , Primers do DNA , DNA Complementar/genética , Regulação da Expressão Gênica/efeitos dos fármacos , Humanos , Masculino , Mesocricetus , Microssomos Hepáticos/efeitos dos fármacos , Modelos Animais , Dados de Sequência Molecular , Regiões Promotoras Genéticas/efeitos dos fármacos , Mapeamento por RestriçãoRESUMO
A novel animal model of insulin resistance, the fructose-fed Syrian golden hamster has been previously documented to exhibit considerable hepatic very-low-density lipoprotein (VLDL) overproduction concomitant with the development of whole body insulin resistance. Here, we investigated whether hepatic lipoprotein overproduction can be ameliorated by treatment with a hydroxymethyl glutaryl conenzyme A (HMG-CoA) reductase inhibitor, atorvastatin, using a series of ex vivo experiments. Hamsters were fed a fructose-enriched diet for 14 days to induce a state of insulin resistance, and then continued on a fructose-enriched diet supplemented with or without 40 mg/kg atorvastatin per day for 14 days. Fructose feeding in the first 2 weeks caused a significant increase in plasma total cholesterol and triglyceride levels. There was a significant decline in plasma triglyceride levels following supplementation with the inhibitor (50% to 59%; P <.05). Experiments with primary hepatocytes revealed a decreased VLDL-apolipoprotein B (apoB) production (37.4% +/- 10.4%; P <.05) in hamsters treated with atorvastatin. Interestingly, atorvastatin treatment partially attenuated (by 23%) the elevated hepatic level of microsomal triglyceride transfer protein (MTP) induced by fructose feeding. There was molecular evidence of improved hepatic insulin sensitivity with atorvastatin treatment based on assessment of the phosphorylation status of the insulin receptor and the expression of protein tyrosine phosphatase-1B. The improvement in insulin signaling was not mediated by a change in hepatic triglyceride accumulation as no significant difference was observed in liver triglyceride levels. Taken together, these data suggest that statins can ameliorate the VLDL-apoB overproduction state observed in a fructose-fed, insulin-resistant hamster model, and may potentially contribute to an enhanced hepatic insulin sensitivity.